Anonymised PE-Backed IVF Chain — Healthcare Growth Operating System

Client profile: PE-backed IVF chain · 5 centres across Delhi NCR, Mumbai, Bangalore, Hyderabad · ₹120 crore annual revenue · PE ownership 30 months at engagement start · PE investor mandate: marketing infrastructure must be "investment-grade" before next funding round · CMO newly appointed 4 months prior to engagement.

The investor mandate that started the engagement

The PE operating partner put it simply in the first call: "We have invested in a healthcare brand with excellent clinical outcomes and broken marketing infrastructure. Before we take this to Series B, I need to know that the marketing system is investment-grade. Right now, it is not."

What "not investment-grade" looked like in practice: 5 IVF centres, 5 different CRM systems (2 Excel spreadsheets, Practo Ray for 1 centre, HubSpot for 1 centre, and a custom-built system for the fifth that nobody could fully explain). No unified attribution. No CPQL measurement. No ability to tell the PE board which of the 5 centres was performing efficiently and which was consuming capital without proportionate return.

The CPQL across the chain was reported as ₹1,840 — but this was a blended CPL, not a CPQL. When ICG mapped the actual attended consultation rates, the real CPQL was ₹2,120. And it varied wildly by centre: the Delhi NCR centre was at ₹1,560; the Mumbai centre at ₹2,480; the Hyderabad centre at ₹2,840.

The PE investor was funding marketing at the Hyderabad CPQL level for the entire chain.

The Growth OS deployment

Unified CRM architecture (weeks 1–12): All 5 CRM systems migrated to Nexus CRM with unified CPQL tracking. Lead-to-consultation-to-procedure pipeline configured per centre, per archetype (primary infertility, secondary infertility, male-factor, international diaspora). Consultation attendance confirmation flowing from each centre's reception system into Nexus via WhatsApp confirmation.

Beacon CAPI full-stack deployment (weeks 3–10): Meta CAPI and Google Enhanced Conversions deployed across all 5 centre accounts simultaneously. EMQ across the chain: 4.0–4.4 (pixel-only) → 7.6–8.2 (post-Beacon, 6 weeks). Attribution window: 180 days across all IVF accounts (ART Act 2021 compliant — no success rate claims in any campaign, ever).

Archetype-specific campaign architecture (weeks 9–16): 4 separate campaign archetypes per centre:

1. Primary infertility, urban professional (Google Search + Instagram, 28–42 demographic)
2. Secondary infertility (Google Search, higher urgency, 30–60 day consideration)
3. Male-factor infertility (destigmatised Google Search campaigns, specific symptom queries)
4. International diaspora (Gulf-targeted Meta with Arabic + English creative, WhatsApp 4-Bot Arabic language flow)

Hawk deployment (weeks 13–16): 90-day re-engagement sequences across all 5 centres. IVF limbo rate at baseline: 34% of monthly leads. Hawk touchpoints: day 7 (warm check-in), day 21 (educational WhatsApp), day 45 (appointment offer), day 75 (final re-engagement).

YODA YouTube programme (month 2 onward): Named embryologist at the Delhi NCR centre as the primary YouTube content lead. 8 educational videos in the first 3 months (ART Act compliant — no success rate claims, YODA-identified patient question format). YODA attribution via video-specific WhatsApp links.

AEO/LLM citation programme (month 3 onward): FAQPage schema on all 5 centre websites. IVF cost transparency pages for each city (most-cited content type for IVF queries in ChatGPT/Perplexity). Named embryologist Person schema with sameAs verification chain.

Outcomes

Month 6:

• Unified Nexus CRM live across all 5 centres
• Blended chain CPQL: ₹2,120 → ₹1,640 (23% reduction; Beacon learning)
• Per-centre CPQL now visible: Delhi NCR ₹1,280, Mumbai ₹1,820, Hyderabad ₹2,040
• Budget reallocated: Delhi NCR and Mumbai weighting increased; Hyderabad architecture redesigned
• Hawk recovery rate: 21% of monthly limbo leads rebooked (0 additional media spend)

Month 9:

• Blended chain CPQL: ₹1,420
• First LLM citation rate report from AIO Intel Tool: 18% of 120 target IVF queries showing ICG-structured pages cited in Google AIO, ChatGPT, or Perplexity
• YouTube: 12 organic consultations/month (Delhi NCR YODA programme, month 7)
• ART Act compliance: zero Section 26 violations across the chain since engagement start

Month 12:

• Blended chain CPQL: ₹1,040 — 51% below the ₹2,120 engagement-start baseline
• Per-centre range: Delhi NCR ₹820, Mumbai ₹1,180, Bangalore ₹1,020, Hyderabad ₹1,260, Chandigarh ₹980
• MRR:CAC ratio: calculated for the first time at 12.6× (was not calculable at engagement start)
• LLM citation rate: 24% of target queries (up from 18% at month 9)
• YouTube organic: 22 consultations/month across 2 centre programmes
• PE board presentation: "marketing infrastructure is investment-grade" — exact phrase used by PE operating partner

The PE partner's assessment

"The CPQL Architecture gave us what we needed: a single, defensible number that connects marketing spend to consultation quality to patient revenue. When we went to our Series B LP meeting, the CPQL trajectory — ₹2,120 at engagement start to ₹1,040 at month 12 — was in the deck as a value-creation milestone. The LLM citation rate was new for the LPs but they understood it immediately: 'we are now visible where patients research before searching.'"

(Paraphrased, anonymised.)

Which ICG products powered this

• Nexus CRM — unified patient pipeline; CPQL tracking as primary metric
• Beacon CAPI — Meta + Google server-side attribution; 180-day IVF attribution window
• Hawk — 34% limbo rate → 21% recovery at ₹0 media cost
• YODA — YouTube attribution; 22 organic consultations/month at month 12
• AIO Intel Tool — LLM citation monitoring; 24% citation rate at month 12
• Agency OS — unified chain-level CPQL dashboard; PE board-ready monthly report

ART Act 2021 Section 26 compliant throughout. Zero success rate claims in any content or campaign.